HIMS Stock Recent News

Both companies revolve around subscription-based services. Hims & Hers is witnessing high-double-digit growth, and profits are soaring.

Eli Lilly is discounting Zepbound, potentially undercutting a growing business for Hims & Hers. Pharma companies are starting to sell more drugs direct-to-consumer, threatening traditional pharmacies.

Hims & Hers has carved a strong niche in the men's healthcare segment while expanding into other areas. The weight-loss category is a huge opportunity for the company.

The new option is priced at a 50% or more discount compared to other weight-loss drugs.

After a strong start to the year, the stock is down 30% since June.

Hims & Hers Health, Inc. reported booming sales in Q2, but the stock fell due to possible confusion on compounded GLP-1 drug sales. The online health and wellness platform dramatically hiked Q3 sales targets to over $375 million. The stock would trade at $41 based on trading at just 5x EV/S targets.

Hims & Hers stock has dropped ~30% from recent peaks despite raising its outlook for FY24. Investors are concerned over projections for the company's weight loss compound drugs, especially if the FDA-approved Wegovy and Ozempic see better supply. Still, the company's weight loss revenue is only contributing a small fraction of its outstanding growth rates today, built across a wide range of specialties.

Subscriber growth reaccelerated, focus on personalized products, over 40% subscribers use personalized solutions. Stock-based compensation concern, $100M buyback program, increased marketing spend, positive outlook for Hims' future. GLP-1 offering still in a gray area, path forward looks difficult but possible.

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

While the stock market has been volatile lately, quality businesses are still performing. Hims & Hers Health is profitable and rapidly expanding its subscriber base.